Doc, I really love Big Mac's, don't you think you could just give me one of those cholesterol pills?

Risk Reduction

- Lifestyle Modification
 - Lower lipids
 - Lower blood pressure
 - Improved cardiovascular function
 - Weight reduction
 - Increased selfesteem
 - Evidence based

- Medication
 - Lower lipids
 - Plaque stabilization
 - Reduced coronary artery disease mortality
 - Evidence based

Acute Coronary Syndromes

Capital Conference 2004
Dr. Raj Woolever, MAJ USAF
MC
Spangdahlem Air Base,
Germany

Cardiovascular Disease

- Leading cause of death in the US
- Over 5 million ER visits for chest pain
- Over 2 million hospitalizations
- Of those admitted:
 - 25% mortality
 - 45% women
 - 60% over age 65
- Annual cost of over \$300 billion

Objectives

- Delineate the full spectrum of acute coronary syndromes
- Explain the pathophysiology of acute coronary syndromes
- Identify historical, physical exam, laboratory and EKG data that contribute to the diagnosis of an acute coronary syndrome
- Discuss an evidence based management plan and optimal treatment for patients with acute coronary syndromes

Acute Coronary Syndromes

- Represent a spectrum of ischemic myocardial events that share similar pathophysiology
 - Unstable Angina
 - Non-ST Elevation Myocardial Infarction
 - ST Elevation Myocardial Infarction

Unstable Angina

- Includes new onset angina, crescendo angina or angina at rest or with minimal exertion
- Caused by a non-occlusive thrombus
- May have non-specific EKG changes
- Normal cardiac enzymes

Non-ST Elevation Myocardial Infarction

- Symptoms similar to unstable angina
- Sufficient vascular occlusion to result in tissue damage and mild myocardial necrosis
- ST depression and/or T-wave inversion on EKG
- Elevated cardiac enzymes

ST Elevation Myocardial Infarction


- Symptoms similar to unstable angina
- May have associated severe pain/pressure, shortness of breath, diaphoresis, nausea
- Caused by complete vessel occlusion resulting in myocardial necrosis
- ST elevations on EKG
- Elevated cardiac enzymes

Pathophysiology Atherosclerotic Plaque


- Lipid-rich core
- Embedded in coronary intima
- Luminal surface with a fibrous cap
- Fibrous cap most vulnerable at its shoulder
- Stability degraded by inflammation, enzymatic processes



Pathophysiology



ACC/AHA Classification of Indications



- Generally agreed to be useful/effective
- Weight of evidence/opinion in favor of efficacy/usefulness
- Efficacy/usefulness less well established by evidence/opinion
- Generally agreed not to be useful/effective and may be harmful

Updated NSTE ACS Guidelines - Weight of Evidence Grades

A

= Data from many large, randomized trials

В

 Data from fewer, smaller randomized trials, careful analyses of nonrandomized studies, observational registries

O

= Expert consensus

- DOE Disease Oriented Evidence
- POEM Patient Oriented Evidence that Matters

- DOE Disease Oriented Evidence
- POEM Patient Oriented Evidence that Matters
 - Mortality

- DOE Disease Oriented Evidence
- POEM Patient Oriented Evidence that Matters
 - Mortality
 - Morbidity

- DOE Disease Oriented Evidence
- POEM Patient Oriented Evidence that Matters
 - Mortality
 - Morbidity
 - Re-hospitalization
 - Functional status
 - Chest pain, shortness of breath

- TIMI...(TACTICS...)
- PURSUIT
- ESPRIT
- TARGET
- GUSTO IV
- NICE
- CURE
- ESSENCE
- CARE
- AVERT

- CAPRIE
- ACUTE
- CHAMP
- PRISM-PLUS
- ISIS-4
- L-CAD
- FRISC II
- HOPE
- MIRACL
- VANQWISH

Risk Stratification

- Cardiac Risk Factors
 - Hypertension
 - Hyperlipidemia
 - Diabetes Mellitus
 - Tobacco use
 - Family History
 - Male < 45</p>
 - ●Female < 55</pre>
 - Obesity
 - Sedentary lifestyle

RISK Stratification


TIMI Risk Score

Predictor of adverse outcomes in those presenting with ACS

- Age > 65
- More than 3 cardiac risk factors
- Prior angiographic coronary obstruction
- ST segment deviation

- More than 2 angina events within the previous 24 hours
- Use of aspirin within previous 7 days
- Elevated cardiac markers

TIMI Risk Score



Clinical Data History

- Characterize symptoms
 - Typical angina
 - Substernal chest discomfort of characteristic quality and duration
 - Pressure, squeezing, radiation, diaphoresis, nausea
 - Provoked by emotional stress or exertion
 - Reduced with rest, nitroglycerine
 - Atypical angina
 - 2 or fewer of above
 - Non-cardiac chest pain
 - 1 or fewer of above

History

- P Palliative/provocative factors
- Quality of discomfort
- Radiation
- S Symptoms associated with discomfort
- T Timing

Clinical Data

Physical Exam

- Measurement of vital signs
 - Blood pressure
 - Pulse
 - Pulse oximetry
 - Temperature
- Focused assessment
 - Cardiovascular system
 - Respiratory system
 - Mental status


Physical Exam

- Increased risk with:
 - Hypotension
 - Tachycardia
 - Pulmonary rales/pulmonary edema
 - New murmurs/heart sounds
 - Diminished peripheral pulses



Search for non-coronary causes of symptoms

Clinical Data




- 12-lead EKG should be obtained WITHIN 10 MINUTES
- Interpret for:
 - T-wave inversions
 - ST depression
 - ST elevation
 - Left bundle branch block



12 - lead EKG within 10 minutes


EKG

- ST Elevation
 - > 0.1mV or 2mm
 - Present in 2 or more contiguous leads
 - EKG change most diagnostic of acute MI
 - Increased mortality with increased number of involved leads



EKG

- Left Bundle Branch Block
 - Intraventricular conduction disturbance
 - Associated with:
 - Ischemia, HTN, cardiomyopathy
 - Obscures accurate interpretation of ST-T segment changes
 - Manage like STEMI




Clinical Data Laboratory

- Troponin
 - Very specific
 - Detects myocardial necrosis/microinfarction
 - More sensitive than CK
 - Begins to rise 4-8 hours after injury
 - Remains elevated for 7-10 days
 - Provides prognostic information



Risk stratification via Troponin I or T

Laboratory Troponin



Laboratory

Creatine Kinase/Creatine Kinase MB Band

- Positive when CK-MB > 5% of total
 CK and/or CK-MB > 2 times normal
- Begins to rise 4-6
 hours after injury
 and peaks at 24
 hours

- Remains elevated for 36-48 hours
- CK-MB elevation is predictive of mortality
- False positives caused by trauma, vigorous exercise, muscle dz. DM. PF. Risk stratification via CK/CK-MB

Risk stratification via total CK w/o ME

Laboratory

- Myoglobin
 - Begins to rise at 2-4 hrs and peaks at 6-12
 - Remains elevated for 24-36 hrs
 - 25-40% rise over 1-2 hrs strongly suggestive of MI
 - Not cardiac specific

- CK Isoforms
- CK-MB1
 - Released w/in 1 hr after MI
- CK-MB2
 - Begins to rise by 2-4 hrs and peaks at 6-9
- Positive when MB2:MB1 > 1.7

Risk stratification via Myoglobin or CK Isoforms MB1/MB2



- 54 y.o. male smoker with hx of HTN, HLP
- Presents to your clinic
- 2 week hx of worsening exertional chest pressure, sometimes radiating to left shoulder, mild chest pain now after walk from parking lot

- 54 y.o. male with hx of HTN, HLP
- Presents to your clinic
- 2 week hx of worsening exertional chest pressure, sometimes radiating to left shoulder, mild chest pain now after walk from parking lot

- Vital signs
 - BP 152/94
 - Pulse 100
 - Pulse ox 94%
- Exam
 - Lungs CTA
 - Heart-RRR, noM/G/R
 - Mental status A&O

- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)

- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)
 - EKG within 10 minutes

- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)
 - EKG within 10 minutes
 - Refer, arrange transport


- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)
 - EKG within 10 minutes
 - Refer, arrange transport
 - Aspirin

- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)
 - EKG within 10 minutes
 - Refer, arrange transport
 - Aspirin
 - Oxygen


- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)
 - EKG within 10 minutes
 - Refer, arrange transport
 - Aspirin
 - Oxygen
 - Start IV

- Outpatient setting
 - Only 2 % of patients with chest pain ultimately diagnosed w/acute ischemia (12.5% in ER)
 - EKG within 10 minutes
 - Refer, arrange transport
 - Aspirin
 - Oxygen
 - Start IV
 - Draw labs

A Case The EKG



- Convincing symptoms
- Positive cardiac risk factors
- EKG changes
- What is his TIMI Risk Score?



What is the diagnosis?

- What is the diagnosis?
 - Unstable Angina or Non ST Elevation MI
 - Cardiac enzymes confirm the diagnosis


- What is the diagnosis?
 - Unstable Angina or Non ST Elevation MI
 - •Cardiac enzymes confirm the diagnosis
- What will he need when he sees you for follow-up?

- What is the diagnosis?
 - Unstable Angina or Non ST Elevation MI
 - Cardiac enzymes confirm the diagnosis
- What will he need when he sees you for follow-up?
 - Lifestyle modification
 - Review HTN, HLP management
 - Aspirin, Plavix

- Initiation of treatment is time sensitive
 - Of MI deaths:
 - •52% are pre-hospital
 - 19% are within first 24 hours
 - 8% are within 24-48%
 - 21% occur within 30 days
- Delay in treatment results from:
 - Late presentation
 - Prolonged pre-hospital evaluation and transport
 - Emergency department

Indicated for all ACS Patients

- Aspirin
 - 160-325mg chewed and swallowed
 - Irreversible blockage of platelet aggregation
 - Plaque stabilization and arrest of thrombus formation
 - Indicated for full spectrum of ACS'
 - 23% reduction in mortality for patients
 - with STEMI



Anti-thrombotic therapy with Aspirin

- Oxygen
 - 2-4 liters of 100% oxygen
 - May limit ischemic myocardial damage by increasing oxygen delivery
 - Supplemental O2 for all ACS patients
 - Supplemental O2 if cyanosis, resp dist, p-ox<9
- Analgesia
 - Morphine sulfate at 4-8mg IV
 - Reduction of pain/anxiety thus decreasing sympathetic tone, systemic vascular resistance and oxygen demand

IV Morphine if persistent sx or severe agitation

• Nitrates

- 0.4mcg sub-lingual or spray or IV infusion
- Infusion titrated to keep patient pain-free
- Increase blood flow to the myocardium by dilating the coronary vessels
- Reduce systemic vascular resistance and preload via veinous system dilation
- Primary indications are for recurrent ischemia, uncontrolled HTN, acute MI

G

- Beta-Blockers
 - May administer PO or IV
 - More benefit IV
 - Improved survival for NSTEMI and STEMI
 - Greatest benefit when started w/in first 24 hrs



zecUse of beta-blockers

- Heparin
 - Important anti-thrombus activity via thrombin de-activation
 - Should be used in addition to Aspirin

Heparin, UFH or LMWH, use



IV UFH or sub-cutaneous LMWH



LMWH use

Newer Medications with Specific Indications

- Clopidogrel
 - 75mg per day
 - Continue for at least one month after event
 - Inhibits platelet aggregation
 - Can be used in conjunction with Aspirin, Heparin for UA/NSTEMI if noninterventional approach planned
 - Should be stopped 5-7 days prior to



Use of Clopidogrel if ASA sensitivity

Use of ASA and Clopidogrel for 9 mo's after eve



Newer Medications with Specific Indications

- Glycoprotein IIb/IIIa Inhibitors
 - Inhibit platelet aggregation
 - Not indicated for STEMI
 - Greatest benefit, in conjunction with Aspirin and Heparin, for those with planned intervention
 - May also be beneficial with other high risk features w/out planned intervention



- Thrombolytics
 - Cornerstone of non-invasive treatment of STEMI
 - Should be initiated within 30 minutes of patient presentation
 - Not indicated for NSTEMI

Indications

- ST segment elevation >1mm in 2 contiguous leads
- New LBBB
- Symptoms consistent with ischemia
- Symptom onset less than 12 hrs prior to presentation

Contraindications

- Previous hemorrhagic CVA
- Known intracranial neoplasm
- Active internal bleeding
- Suspected aortic dissection
- Plus relative contraindications

- Limitations
 - Operator dependent
 - Not universally available
- Benefits
 - Minimally invasive
 - Prompt vessel opening
 - Best option for select patients

Percutaneous Intervention Recommended treatment for UA/NSTEMI in patients with:

- Recurrent angina at rest or w/minimal exertion despite aggressive treatment
- Elevated Troponin
- New ST segment depression
- Recurrent angina with CHF symptoms

- High risk findings on non-invasive stress testing
- Decreased LV function
- Hemodynamic instability
- Sustained V-tach
- Hx of PCI w/in last 6 mo's or prior CABG



Prevention

- Lifestyle modification
 - Dietary counseling
 - DASH Dietary Approaches to Stop Hypertension
 - Exercise prescription
 - Smoking cessation
 - Cardiac rehabilitation

Prevention

- Health care maintenance
 - Routine screening
 - Weight
 - Blood pressure
 - Lipids
 - •Glucose
 - Metabolic Syndrome

The Family Physician

- Able to tailor treatments and interventions for specific patients
- Able to focus on prevention
- Able to make appropriate health care maintenance and screening recommendations
- Able and willing to focus on lifestyle modifications